Protalix BioTherapeutics awarded executive Naos Yaron 168,000 derivative securities across two transactions on 2026-09-03 at $0 per share. Yaron owned 56,000 derivative securities after the transactions, giving investors a specific view of the executive’s reported derivative-security position and the award’s recorded transaction terms.

Key Highlights

  • Naos Yaron owned 56,000 derivative securities after the transactions.
  • The transactions were recorded at $0 per share.
  • Yaron serves as Protalix BioTherapeutics’ Sr. VP and COO.

Protalix BioTherapeutics, Inc. (AMEX: PLX) awarded Naos Yaron 168,000 derivative securities across two transactions. The transactions took place on 3 September 2026 at $0 per share.

168,000 Derivative Securities Awarded

Naos Yaron, the company’s Sr. VP and COO, received the derivative securities through two separate transactions. Both transactions carried transaction code A. The recorded price was $0 per share. Yaron owned 56,000 derivative securities following the transactions.